Can CDMOs Provide Leadership In Cell And Gene Therapy?

By Marwan Alsarraj and Mark White, PhD

Many cell and gene therapies would never make it to market without the expertise and capabilities of contract development and manufacturing organizations (CDMOs) operating behind the scenes. As of June 2021, 14 cell and gene therapies have been approved for clinical application in the United States, and over 400 more are in various stages of clinical trials. The hopes of many patients hinge on the success of these various programs, which are designed to deliver a significant advance on existing treatments or even a functional cure.

As these promising biologics continue to gain momentum, we spoke with industry experts to find out how CDMOs are:

• Adding value through stability and development expertise
• Developing meaningful, productive partnerships with innovators
• Implementing the latest technologies for cell and gene therapy